Feasibility of Semaglutide in Advanced Lung Disease

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT05746039
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight? Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

Key Dates

Start date
Jan 29, 2024
Status verified
Apr 2026
Primary completion
Dec 28, 2027
Completion
Dec 28, 2027

Study Design

Enrollment
8 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Study Drug (semaglutide)
    Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy

Primary Outcome Measure

Tolerability [ Time Frame: 12 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Pennsylvania Perelman School of MedicinePhiladelphiaPennsylvania19104

Find similar trials in Philadelphia, PA

By condition
COPDObesity / overweight
By specialty
PulmonologyLung diseaseEndocrinologyMetabolic healthWeight loss
By research site
University of Pennsylvania Perelman School of Medicine· Philadelphia, PA

Related Studies